Pretransplantation Respiratory Syncytial Virus Infection: Impact of a Strategy to Delay Transplantation
Open Access
- 1 September 2004
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 39 (5) , 673-680
- https://doi.org/10.1086/422994
Abstract
Background. Delay of hematopoietic stem cell transplantation (HSCT) has been suggested if upper respiratory tract infection (URTI) due to respiratory syncytial virus (RSV) occurs in transplantation candidates, but the efficacy of this strategy in preventing posttransplantation RSV infection is unknown. Methods. In a retrospective study, we reviewed charts of patients who underwent transplantation at Fred Hutchinson Cancer Research Center (Seattle, WA) during the period of June 1987 through December 2000 and evaluated the strategy of delaying HSCT in candidates with laboratory-confirmed RSV URTI. Results. Thirty-one of 37 patients had RSV URTI before conditioning, 2 (6.5%) of whom developed RSV infection after HSCT. In 6 of 37 patients, symptoms of URTI were present during the start of conditioning, but RSV virologic confirmation occurred a median of 4.5 days (range, 2–5 days) into the conditioning regimen. Conditioning was aborted for 3 of 6 patients; none had progression to RSV pneumonia. Of the 3 patients in whom HSCT proceeded as scheduled, 2 developed RSV pneumonia. Overall, RSV pneumonia occurred in 1 of 34 patients for whom HSCT was delayed, compared with 2 of 3 patients for whom there was no delay (P = .01). Conclusions. In patients with pretransplantation RSV URTI, delay of HSCT was associated with a lower risk of pneumonia than was no delay. Because URTIs can progress to severe complications in patients receiving HSCTs, these results support Centers for Disease Control and Prevention/American Society of Blood and Marrow Transplantation recommendations that HSCT be delayed on the basis of symptoms of URTI rather than waiting for virologic confirmation.Keywords
This publication has 11 references indexed in Scilit:
- The natural history of respiratory syncytial virus infection in cancer and transplant patients: implications for managementBlood, 2004
- Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategiesTransplantation and Cellular Therapy, 2003
- Respiratory virus infections in transplant recipients after reduced‐intensity conditioning with Campath‐1H: high incidence but low mortalityBritish Journal of Haematology, 2002
- Community-acquired respiratory syncytial virus and parainfluenza virus infections after hematopoietic stem cell transplantation: The Fred Hutchinson Cancer Research Center experienceTransplantation and Cellular Therapy, 2001
- Respiratory virus infections in stem cell transplant patients: The European experienceTransplantation and Cellular Therapy, 2001
- Phase 1 Evaluation of the Respiratory Syncytial Virus–Specific Monoclonal Antibody Palivizumab in Recipients of Hematopoietic Stem Cell TransplantsThe Journal of Infectious Diseases, 2001
- Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trialBlood, 2000
- Patients with multiple myeloma may safely undergo autologous transplantation despite ongoing RSV infection and no ribavirin therapyBone Marrow Transplantation, 1999
- Respiratory Virus Infections After Marrow Transplant: The Fred Hutchinson Cancer Research Center ExperienceThe American Journal of Medicine, 1997
- Community Respiratory Virus Infections Among Hospitalized Adult Bone Marrow Transplant RecipientsClinical Infectious Diseases, 1996